Three cachexia phenotypes and the impact of fat‐only loss on survival in FOLFIRINOX therapy for pancreatic cancer

By the traditional definition of unintended weight loss, cachexia develops in ~80% of patients with pancreatic ductal adenocarcinoma (PDAC). Here, we measure the longitudinal body composition changes in patients with advanced PDAC undergoing 5‐fluorouracil, leucovorin, irinotecan, and oxaliplatin therapy.

[1]  S. Anker,et al.  Ethical guidelines for publishing in the journal of cachexia, sarcopenia and muscle: update 2017 , 2017, Journal of cachexia, sarcopenia and muscle.

[2]  Tore Wentzel-Larsen,et al.  Skeletal muscle radiodensity is prognostic for survival in patients with advanced non-small cell lung cancer. , 2016, Clinical nutrition.

[3]  T. Zimmers,et al.  Cancer and Chemotherapy Contribute to Muscle Loss by Activating Common Signaling Pathways , 2016, Front. Physiol..

[4]  Erich P Huang,et al.  RECIST 1.1-Update and clarification: From the RECIST committee. , 2016, European journal of cancer.

[5]  T. Zimmers,et al.  STAT3 in the systemic inflammation of cancer cachexia. , 2016, Seminars in Cell and Developmental Biology.

[6]  T. Zimmers,et al.  Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs , 2016, Oncotarget.

[7]  D. Lobo,et al.  The impact of sarcopenia and myosteatosis on outcomes of unresectable pancreatic cancer or distal cholangiocarcinoma. , 2015, Clinical nutrition.

[8]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[9]  Y. Bang,et al.  Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index , 2015, PloS one.

[10]  H. Matsubara,et al.  Cancer cachexia, mechanism and treatment. , 2015, World journal of gastrointestinal oncology.

[11]  S. Gaujoux,et al.  Influence of cachexia and sarcopenia on survival in pancreatic ductal adenocarcinoma: a systematic review. , 2015, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[12]  M. McCarter,et al.  Neoadjuvant FOLFIRINOX Application in Borderline Resectable Pancreatic Adenocarcinoma , 2014, Medicine.

[13]  P. Fayers,et al.  Validation of the Consensus-Definition for Cancer Cachexia and evaluation of a classification model--a study based on data from an international multicentre project (EPCRC-CSA). , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  A. Krasinskas,et al.  Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer , 2013, Journal of surgical oncology.

[15]  L. Mccargar,et al.  Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  T. Conroy,et al.  The Role of the FOLFIRINOX Regimen for Advanced Pancreatic Cancer , 2013, Current Oncology Reports.

[17]  R. McWilliams,et al.  Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma. , 2012, JOP : Journal of the pancreas.

[18]  T. Zimmers,et al.  JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia. , 2012, American journal of physiology. Endocrinology and metabolism.

[19]  David Koff,et al.  Accelerated muscle and adipose tissue loss may predict survival in pancreatic cancer patients: the relationship with diabetes and anaemia , 2012, British Journal of Nutrition.

[20]  Michael A. Choti,et al.  Impact of Sarcopenia on Outcomes Following Resection of Pancreatic Adenocarcinoma , 2012, Journal of Gastrointestinal Surgery.

[21]  T. Zimmers,et al.  Obesity and weight loss at presentation of lung cancer are associated with opposite effects on survival. , 2011, The Journal of surgical research.

[22]  R. Hruban,et al.  Pancreatic cancer , 2011, The Lancet.

[23]  T. Zimmers,et al.  STAT3 Activation in Skeletal Muscle Links Muscle Wasting and the Acute Phase Response in Cancer Cachexia , 2011, PloS one.

[24]  I. Sobhani,et al.  5-Fluorouracil/Leucovorin Combined with Irinotecan and Oxaliplatin (FOLFIRINOX) as Second-Line Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma , 2011, Oncology.

[25]  Pierre Michel,et al.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.

[26]  Paula Ravasco,et al.  Definition and classification of cancer cachexia: an international consensus. , 2011, The Lancet. Oncology.

[27]  B. Tan,et al.  Cytokine gene polymorphisms and susceptibility to cachexia , 2010, Current opinion in supportive and palliative care.

[28]  Stephan von Haehling,et al.  Cachexia as a major underestimated and unmet medical need: facts and numbers , 2010, Journal of cachexia, sarcopenia and muscle.

[29]  K. Clément,et al.  Adipose tissue pathways involved in weight loss of cancer cachexia , 2010, British Journal of Cancer.

[30]  T. Zimmers,et al.  Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. , 2010, Biochemical and biophysical research communications.

[31]  Lisa Martin,et al.  Sarcopenia in an Overweight or Obese Patient Is an Adverse Prognostic Factor in Pancreatic Cancer , 2009, Clinical Cancer Research.

[32]  J. Hebebrand,et al.  [Obesity and overweight]. , 2009, Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie.

[33]  Tony Reiman,et al.  A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. , 2008, Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme.

[34]  B. Tan,et al.  Cachexia: prevalence and impact in medicine , 2008, Current opinion in clinical nutrition and metabolic care.

[35]  Tony Reiman,et al.  Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. , 2008, The Lancet. Oncology.

[36]  Jie-shou Li,et al.  Association of IL-6 gene polymorphisms with cachexia susceptibility and survival time of patients with pancreatic cancer. , 2008, Annals of clinical and laboratory science.

[37]  P. Scherer.  Adipose Tissue , 2006, Diabetes.

[38]  S. Anker,et al.  Cachexia and Wasting: A Modern Approach , 2006 .

[39]  Stanley Heshka,et al.  Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. , 2004, Journal of applied physiology.

[40]  T. Zimmers,et al.  Induction of Cachexia in Mice by Systemically Administered Myostatin , 2002, Science.

[41]  J. Niederhuber,et al.  The national cancer data base report on pancreatic cancer , 1995, Cancer.

[42]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[43]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.

[44]  Joseph R. Bertino,et al.  Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. , 1980, The American journal of medicine.

[45]  C. Begg,et al.  Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. , 1980, The American journal of medicine.

[46]  Daan Brandenbarg.  The National. , 1892 .